Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
PURPOSE: The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is active in metastatic melanoma. The addition of cisplatin (CDDP) has resulted in response rates greater than 50%. This study was performed to determine whether the addition of CDDP to a cytokine treatment regimen with IFN alpha and high-dose IL-2 influences survival of patients with metastatic melanoma. PATIENTS AND METHODS: Patients with advanced metastatic melanoma were randomly assigned to receive treatment with IFN alpha 10 x 10(6) U/m2 subcutaneously on days 1 through 5 and a high-dose intravenous decrescendo regimen of IL-2 on days 3 through 8 (18 mIU/ m2/6 hours, 18 mIU/m2/12 hours, 18 mIU/m2/24 hours, and 4.5 mIU/m2/24 hours x 3) without (arm A) or with (arm B) CDDP 100 mg/m2 on day 1. Treatment cycles were repeated every 28 days to a maximum of four cycles. RESULTS: One hundred thirty-eight patients with advanced metastatic melanoma, of whom 87% had visceral metastases, were accrued for the trial. Both regimens were feasible in a multicenter setting. The objective response rate was 18% without and 33% with CDDP (P = .04). The progression-free survival was 53 days without and 92 days with CDDP (P = .02, Wilcoxon; P = .09, log-rank). There was no statistically significant difference in survival between treatment arms, with a median overall survival duration for all patients of 9 months. CONCLUSION: The addition of CDDP to cytokine treatment with IFN alpha and IL-2 does not influence survival of patients with advanced metastatic melanoma, despite a significant increase in response rate and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., & White, D. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1863 · Cited by 374
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1338 · Cited by 257
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., & Doroshow, J. H. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1650 · Cited by 198
Current therapy for malignant melanoma.
Ss, L. (1989) · Seminars in Oncology · Cited by 144
Atkins, M. B., O’Boyle, K., Sosman, J. A., Weiss, G. R., Margolin, K. A., Ernest, M. L., Kappler, K., Mier, J. W., Sparano, J. A., & Fisher, R. I. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1553 · Cited by 128
Studies of interferons in the therapy of melanoma.
Kirkwood, J. M. (1991) · PubMed · Cited by 68
Lichtenstein, A. K., & Pende, D. (1986) · PubMed · Cited by 55
Kruit, W. H. J., Punt, K. J., Goey, S. H., de Mulder, P. H., Hoogenhuyze, D. C. A. V., Henzen‐Logmans, S. C., & Stoter, G. (1994) · Cancer · Cited by 55
Self-citationCreagan, E. T., Schaid, D. J., Ahmann, D. L., & Frytak, S. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12875512 · Cited by 43
Keilholz, U., Scheibenbogen, C., Stoelben, E., Saeger, H., & HUNSTEIN, W. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90122-8 · Cited by 34
Self-citationKruit, W., Punt, C. J. A., Goey, S. H., de Mulder, P., Gratama, J., Eggermont, A. M. M., Bolhuis, R., & Stoter, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.463 · Cited by 26
Self-citationSequential Dacarbazine/Cisplatin and Interleukin-2 in Metastatic Melanoma
Redman, B. G., Flaherty, L. E., Chou, T., et al. (1991) · Journal of Immunotherapy · doi:10.1097/00002371-199104000-00009 · Cited by 24
Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855
Role of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Jonasch, E., & Haluska, F. G. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-34 · Cited by 518
Agarwala, S. S., & Kirkwood, J. M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-144 · Cited by 330
Eigentler, T. K., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 324
Metadata
- Authors
- Keilholz, U., Goey, S. H., Punt, C. J., Proebstle, T. M., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Liénard, D., Enk, A., Dummer, R., Hantich, B., Geueke, A. M., & Eggermont, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-07
- Volume
- 15
- Issue
- 7
- Pages
- 2579-2588
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106428332
- Cited by
- 193
- References
- 15
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.